Business · 12/01/2001Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Synvisc Hylan G-F 20 Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for Synvisc Hylan G-F 20, a medical device, in order to extend its patent protection, as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →